NovoCare Pharmacy (Wegovy) vs Yucca Health (2026): prices, structure, verdict

On tirzepatide, only Yucca Health↗ has a rankable figure: $258 a month all-in; NovoCare Pharmacy (Wegovy)↗ does not offer tirzepatide.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, Yucca Health is cheaper: $146 versus $349 a month all-in — a $203 monthly gap, $2,436 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

NovoCare Pharmacy (Wegovy): the record, condensed

On semaglutide, the number that matters at NovoCare Pharmacy (Wegovy) is $349 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $349 is the whole subscription, which makes NovoCare Pharmacy (Wegovy) unusually easy to compare and unusually easy to leave.

To place the number: #0 of 20 verified programs, with the floor $216/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth nothing a month — at which point brand deserves the first look. A year at this figure: $4,188 monthly-billed.

Operationally at NovoCare Pharmacy (Wegovy): shipping included (or retail via savings card); commitment none; cancellation no subscription; pharmacy named (Novo Nordisk direct / retail partners); states: 50 states; evidence source-verified, captured 2026-08-10. The full record with source and archive links: the NovoCare Pharmacy (Wegovy) page · visit NovoCare Pharmacy (Wegovy) ↗

Yucca Health: the record, condensed

Start with the load-bearing figure: $258 a month, all-in, is what Yucca Health charges for tirzepatide at the 10 mg basis. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $258 is the whole subscription, which makes Yucca Health unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #2 of 17 in the verified tirzepatide index — $43/month above the floor (NexLife↗, $215) — and sits $191 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $3,096.

Yucca Health’s semaglutide program bills $146 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at Yucca Health is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #2 of 20 verified programs, with the floor $13/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $203 a month. A year at this figure: $1,752 monthly-billed.

Operationally at Yucca Health: shipping included; commitment 6-month term; cancellation 6-month term applies; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the Yucca Health page · visit Yucca Health ↗

Semaglutide: the duel in full

Put the two semaglutide figures side by side and hold them there: Yucca Health at $146, NovoCare Pharmacy (Wegovy) at $349 — a $203 monthly spread that compounds to $2,436 over a maintenance year and $4,872 over two.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $203 gap is exactly what it appears to be.

Translate the $203/month spread into medication: $2,436 a year equals roughly 16.7 months of therapy at the cheaper program’s rate. That is the honest unit for gaps in this market — months of treatment, not abstract dollars — and it is why small-looking monthly differences decide long courses.

On best published rate — the lower of each program’s month-to-month price and its labeled 12-month-plan rate, which is the sort most price roundups quietly run — the duel reads: NovoCare Pharmacy (Wegovy) $349/mo month-to-month versus Yucca Health $146/mo month-to-month. Same winner on both bases — Yucca Health leads whether you compare month-to-month prices or committed-plan rates, which makes this one of the cleaner verdicts in the index. Prepaid rates are upfront commitments with refund terms to verify before they count.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: NovoCare Pharmacy (Wegovy) $1,047 monthly; Yucca Health $438 monthly — best path favors Yucca Health by $609. 6 months: NovoCare Pharmacy (Wegovy) $2,094 monthly; Yucca Health $876 monthly — best path favors Yucca Health by $1,218. 12 months: NovoCare Pharmacy (Wegovy) $4,188 monthly; Yucca Health $1,752 monthly — best path favors Yucca Health by $2,436. 24 months: NovoCare Pharmacy (Wegovy) $8,376 monthly; Yucca Health $3,504 monthly — best path favors Yucca Health by $4,872.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

§ Structure vs structure

Everything besides the price

Coverage: NovoCare Pharmacy (Wegovy) publishes “50 states”; Yucca Health publishes “not published” — for anything short of an explicit 50-state claim, intake is the final word.

Pharmacy transparency splits them: NovoCare Pharmacy (Wegovy) names its network (Novo Nordisk direct / retail partners); Yucca Health does not, which shifts the burden of verification onto your intake questions.

Exit terms: NovoCare Pharmacy (Wegovy) — none; no subscription. Yucca Health — 6-month term; 6-month term applies.

Evidence: NovoCare Pharmacy (Wegovy) source-verified (captured 2026-08-10); Yucca Health source-verified (2026-08-05).

A rule that has held across this index: disclosure predicts disclosure. Whichever of these two publishes more — pharmacies, states, exit terms — is usually the one whose invoice matches its ad.

§ If you move

Switching between NovoCare Pharmacy (Wegovy) and Yucca Health

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (NovoCare Pharmacy (Wegovy): no subscription; Yucca Health: 6-month term applies) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings